RPRX logo

Royalty Pharma (RPRX) EV/EBITDA

EV/EBITDA:

10.16-0.24(-2.31%)
May 20, 2025

Summary

  • As of today (May 21, 2025), RPRX EV/EBITDA is 10.16, with a fall of -0.24 (-2.31%) during the most recent trading session on May 20, 2025.
  • Over the past year, RPRX EV/EBITDA has dropped by -2.74 (-21.24%).
  • RPRX EV/EBITDA is now -81.35% below its all-time high of 54.48.

Performance

RPRX EV/EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

OtherRPRXvaluation metrics

EV/EBITDA Formula

EV/EBITDA =  
Enterprise Value
TTM EBITDA

RPRX EV/EBITDA Trends

PeriodPeriodEV/EBITDAEV/EBITDAEnterprise valueEnterprise valuePricePrice
todaytoday-2.3%-2.3%-3.4%
1 m1 month-0.9%-0.9%+1.5%
3 m3 months-25.1%-3.1%-0.7%
6 m6 months+6.4%+11.6%+26.2%
ytdytd-12.4%+13.4%+29.7%
1 y1 year-21.2%+15.7%+20.4%
5 y5 years---

RPRX EV/EBITDA Highs & Lows

PeriodPeriodHighHighCurrent vs highvs highLowLowCurrent vs lowvs low
1 m1-month10.40-2.3%9.96+2.0%
3 m3-month13.76-26.2%9.76+4.1%
6 m6-month13.76-26.2%9.14+11.2%
1 y1-year15.62-35.0%9.14+11.2%
3 y3-year54.48-81.3%9.14+11.2%
5 y5-year54.48-81.3%5.90+72.2%
alltimeall time54.48-81.3%5.90+72.2%

RPRX EV/EBITDA History

DateValue
2025
10.16(-12.4%)
2024
11.60(+20.5%)
2023
9.63(-82.2%)
DateValue
2022
54.07(+239.0%)
2021
15.95(+23.8%)
2020
12.88

FAQ

  • What is Royalty Pharma EV/EBITDA?
  • What is the all time high EV/EBITDA for Royalty Pharma?
  • What is RPRX EV/EBITDA year-to-date change?
  • What is Royalty Pharma EV/EBITDA year-on-year change?

What is Royalty Pharma EV/EBITDA?

The current EV/EBITDA of RPRX is 10.16

What is the all time high EV/EBITDA for Royalty Pharma?

Royalty Pharma all-time high EV/EBITDA is 54.48

What is RPRX EV/EBITDA year-to-date change?

Royalty Pharma EV/EBITDA has changed by -1.44 (-12.41%) since the beginning of the year

What is Royalty Pharma EV/EBITDA year-on-year change?

Over the past year, RPRX EV/EBITDA has changed by -2.74 (-21.24%)
On this page